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ABSTRACT
Introduction The Canadian Bronchiolitis Epinephrine
Steroid Trial (CanBEST) and the Bronchiolitis Severity
Cohort (BSC) study enrolled infants with bronchiolitis
during the first year of life. The CanBEST trial suggested
that treatment of infants with a combined therapy of high-
dose corticosteroids and nebulised epinephrine reduced
the risk of admission to hospital. Our study aims to—(1)
quantify the risk of developing asthma by age 5 and 10
years in children treated with high-dose corticosteroid and
epinephrine for bronchiolitis during infancy, (2) identify risk
factors associated with development of asthma in children
with bronchiolitis during infancy, (3) develop asthma
prediction models for children diagnosed with bronchiolitis
during infancy.
Methods and analysis We propose a longitudinal
cohort study in which we will link data from the
CanBEST (ISRCTN56745572, post-results) and BSC
study with routinely collected data from provincial health
administrative databases. Our outcome is asthma incidence
measured using a validated health administrative data
algorithm. Primary exposure will be treatment with a
combined therapy of high-dose corticosteroids and
nebulised epinephrine for bronchiolitis. Covariates will
include type of viral pathogen, disease severity, medication
use, maternal, prenatal, postnatal and demographic factors
and variables related to health service utilisation for acute
lower respiratory tract infection. The risk associated with
development of asthma in children treated with high-dose
corticosteroid and epinephrine for bronchiolitis will be
assessed using multivariable Cox proportional hazards
regression models. Prediction models will be developed
using multivariable logistic regression analysis and
internally validated using a bootstrap approach.
Ethics and dissemination Our study has been approved
by the ethics board of all four participating sites of the
CanBEST and BSC study. Finding of the study will be
disseminated to the academic community and relevant
stakeholders through conferences and peer-reviewed
publications.

Strengths and limitations of this study
►► Our study provides an opportunity to specifically

examine whether treatment of infants with bronchiolitis with combined high-dose corticosteroids and
nebulised epinephrine reduces the risk of future
asthma.
►► Linkage of data from clinical studies to health service utilisation data may provide objective, prospectively collected measures and outcomes that are
free of recall bias and minimise loss to follow-up
and data missingness.
►► Diagnosis of asthma using health service utilisation
data is a proxy method, but we will use a validated
health-administrative algorithm for the detection of
asthma.

INTRODUCTION
A multitude of controlled follow-up studies
has established that viral bronchiolitis during
infancy is associated with on-
going respiratory morbidity. Infants with bronchiolitis
have an increased risk of developing wheeze-
associated disorders, including asthma, in
later life.1 2 Respiratory syncytial virus (RSV) is
the most common aetiological agent detected
in infants with bronchiolitis.3 Studies have
shown 20%–54% of infants with bronchiolitis develop asthma.4–12 A multivariate evaluation of possible risk factors for asthma
showed that RSV bronchiolitis during infancy
had the highest independent OR for asthma
(OR: 12.7, 95% CI 3.4 to 47.1).1 However, a
more recent systematic review has reported
that this association may not be causal.13 This
association appears most pronounced during
the first 5 years of life but may extend up to
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upregulate mRNA production of anti-
inflammatory
genes by enhanced translocation of the glucocorticoid
receptor into the nucleus35 36 and (2) corticosteroids
enhance and markedly extend upregulation of mRNA for
regulation of G-protein signalling 2 by ß2-adrenoceptor
agonists.37 Clinical studies in asthma have also demonstrated that combined administration of high-dose corticosteroid and epinephrine results in anti-inflammatory
and bronchoprotective effects that are unachievable by
either drug alone.36 37 Given the potential benefit seen in
the acute management of bronchiolitis and the clinical
and basic science evidence of true synergy between beta-
agonists and corticosteroids, it is important to examine
whether any longer term benefit of such treatment in
acute phase bronchiolitis exists.
Early identification of children who later develop
asthma may improve their quality of life by appropriate
preventive measures, regular monitoring and appropriate
drug treatment.38 Predictive models have been shown to
help physicians to identify asthma, particularly in children under 5 years.39–41 However, the majority of these
prediction models have targeted children in the general
population rather than children with bronchiolitis per
se.41 42 There is evidence to suggest that simple clinical
parameters, such as—age, sex, history of atopy, family
history of asthma and early frequent wheezing during
the first 3 years of life, can identify children at high risk
of developing asthma by age 6, specifically in children
diagnosed with RSV bronchiolitis during infancy.43 In
addition, the level of healthcare utilisation during the
bronchiolitis episode has been found to correlate with
the risk of subsequent asthma, with the greatest risk of
asthma following bronchiolitis hospitalisation.44–46 A
study has shown that children who develop asthma have
high intensity health service utilisation during preschool
years.47
Our proposed study aims to link CanBEST and BSC data
to provincial health administrative databases (HAD). The
unique combination of these data sources can provide
objective, prospectively collected measures and outcomes
that are free of recall bias. Moreover, it minimises loss
to follow-
up and data missingness, as individuals are
consistently followed in HAD. This study will allow us to
examine the long-term effect of high-dose corticosteroid
and epinephrine treatment on the respiratory health of
children diagnosed with bronchiolitis during infancy as
well as develop the most parsimonious asthma prediction
models specifically for children diagnosed with bronchiolitis during infancy. Our three objectives are:
Objective 1: to quantify the risk of developing asthma
by age 5 and 10 years in children treated with high-dose
corticosteroid and epinephrine for bronchiolitis during
infancy.
Objective 2: to identify risk factors associated with the
development of asthma in children diagnosed with bronchiolitis during infancy.
Objective 3: to develop asthma prediction models for
children diagnosed with bronchiolitis during infancy.
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10 years of age.1 14–16 The mechanism through which RSV
contributes to asthma is not fully understood but appears
to relate to the viral injury, disease severity, pre-existing
abnormal lung function, genetic susceptibility, altered
immunology and environmental factors.1 13
A number of risk factors have been found to be associated with the development of asthma among children with
a history of bronchiolitis in early life. These include the
child’s clinical course of bronchiolitis (severity of illness
and viral pathogen), prenatal (maternal asthma control
and smoking during pregnancy) and postnatal factors
(prematurity, congenital heart disease, pre-
existing
impaired lung function, personal history of atopy) and
early childhood (breastfeeding, daycare attendance),
parental (family history of atopy and asthma), household
(moisture, dust, mite, tobacco smoke) and demographic
factors (men, lower socioeconomic status, immigrant
status).1 2 17 18 In addition to these, the pattern of health
service utilisation by children during their preschool
years and the services they receive for prevention of respiratory disorders during the first 2 years of life may also be
associated with later development of asthma.19
It has been postulated that the immune response
followed by viral bronchiolitis may induce long-lasting
detrimental effects and contribute to postbronchiolitis
wheezing and asthma.20–23 For example, severe RSV bronchiolitis in young infant may shift the T-helper (Th)1/
Th2 balance in favour of a Th2 cytokine pattern, leading
to development of allergic sensitisation and persistent
asthma.4 24 As a result, it has been suggested that immune-
modulating drugs such as corticosteroids might prevent
the development of asthma.25 26 Most follow-up studies
in bronchiolitis, however, have found no association
between corticosteroid use and the degree of respiratory
sequelae after bronchiolitis.25–28 However, these studies
primarily examined admitted patients who may have had
more severe disease and were at a later stage in the disease
process. The majority of studies also had relatively small
samples and were likely underpowered to detect possible
beneficial effects. Importantly, corticosteroids alone
appear to have no immediate benefit in the treatment of
bronchiolitis27–29 and, thus, are not recommended for the
treatment of bronchiolitis.30–33
The Canadian Bronchiolitis Epinephrine Steroid Trial
(CanBEST)29 and the Bronchiolitis Severity Cohort
(BSC)34 study enrolled infants with bronchiolitis during
their first year of life. These studies have established
a bronchiolitis cohort where detailed clinical data,
including the management and clinical outcomes for
infants with bronchiolitis, are known. Results from the
CanBEST trial suggested that the combined therapy of
high-
dose corticosteroids and nebulised epinephrine
may reduce admissions to hospital for children with
bronchiolitis through a synergistic effect between the
two medications.29 Basic science evidence supports a
synergistic effect of corticosteroid and epinephrine in
modulating the immune system through several mechanisms: (1) ß2-
adrenoceptor agonists synergistically

Open access

Study population
Our study will include children recruited from Ontario
and Alberta sites of the CanBEST and BSC study (all sites
are members of the research collaboration Pediatrics
Emergency Research Canada). CanBEST and BSC study
recruited participants from paediatric EDs from 2004 to
2007 (CanBEST, N=720; BSCS, N=724). Inclusion criteria
for this study are children who were diagnosed with
bronchiolitis at age ≤12 months and participated in the
CanBEST or BSC study (inclusion and exclusion details
of CanBEST and BSC study available elsewhere).29 34
Exclusion criteria are subjects without a valid Ontario
or Alberta health card number for data linkage, subjects
without an ON or AB residence code (at the time of enrolment into the trial) or those who could not be linked.
Data sources
Clinical data: a bronchiolitis cohort will be created by
pooling data from the CanBEST and BSC study. CanBEST
was a multicentre, double-
blind, placebo-
controlled
randomised trial in which infants with bronchiolitis were
enrolled from nine paediatric EDs across Canada.29 For
our proposed study, data from four sites in two provinces
will be used and linked (total sample size 720; Ontario
sites: Children’s Hospital of Eastern Ontario, Ottawa,
and Children’s Hospital London Health Sciences Centre,
London; Alberta sites: Alberta Children’s Hospital,
Calgary and Stollery Children’s Hospital, Edmonton). In
CanBEST, participants were randomly assigned to one of
four intervention groups. Group 1: epinephrine—high-
dose oral corticosteroid, group 2: epinephrine, group 3:
high-dose oral corticosteroid and group 4: placebo. Total
follow-up was 22 days after enrolment in the study and
the primary outcome was hospital admission up to 7 days
after enrolment. The BSC study cohort (total sample size
for Ontario and Alberta 724) included infants with bronchiolitis who were either ineligible for CanBEST or those
who did not consent to participation in CanBEST.34 The
baseline data for both studies included clinical, demographic, historical and environmental data. Follow-
up
data for children in CanBEST included laboratory investigation for viral pathogen, admission to hospital, length
of hospital stay and intensive care unit (ICU) admission.
The BSC study children received treatment for bronchiolitis following standard guidelines with treatments and
outcomes recorded. These data are currently housed
in a repository in Ontario, at the Children’s Hospital of
Eastern Ontario, Ottawa.
Health administrative data: in Ontario, data from the
bronchiolitis cohort described above will be linked to six
Ontario-based HAD housed and accessible through ICES.
Abdullah K, et al. BMJ Open 2021;11:e048823. doi:10.1136/bmjopen-2021-048823

ICES is an independent non-
profit research institute
whose legal status under Ontario’s health information
privacy law allows it to collect and analyse healthcare and
demographic data, without consent, for health system
evaluation and improvment. The following databases will
be used: (1) Ontario Health Insurance Plan database,
which contains information on all fee-for-service billings
for physician services rendered, (2) National Ambulatory Care Reporting System database (NACRS), which
contains data for hospital-based and community-based
emergency and ambulatory care, (3) Ontario Registered
Persons Database, which includes information on demographics and on the time period for which each participant was eligible to receive publicly funded provincial
healthcare, (4) Discharge Abstract Database (DAD),
which provides information on all acute care hospitalisations; (5) Ontario Asthma Surveillance Information
System (OASIS), a validated registry that uses administrative databases to identify and follow individuals with
asthma; and (6) MOMBABY database, which contains
information from hospital admission records for mothers
linked with their newborns at the time of birth. In Alberta,
the bronchiolitis cohort will be linked to provincial HAD
housed at and accessible through the Enterprise Data
Warehouse, maintained by Alberta Health Services (AHS)
Analytics. The Enterprise Data Warehouse contains the
CIHI DAD, NACRS, Alberta physician claims and Alberta
Pharmaceutical Information Network. AHS Analytics has
created coding that creates a linked data set of all Alberta
mothers and their infants from FY 2002/2003 up to
present day. Children’s health service utilisation data will
be drawn from this linked data set of all Alberta mothers
and their infants.
Data linkage and transfer
Individual records from the bronchiolitis cohort will be
deterministically linked to HAD within each province. In
Ontario, we will use the unique Ontario health insurance
number for linkage and access to data housed at ICES.
In Alberta, the Alberta Unique Lifetime Identifier will be
used to link and access data in Alberta-based HAD housed
in the Enterprise Data Warehouse, AHS. In Alberta, the
data set created for these patients will be deidentified
and transferred via Services Secure File Transfer Protocol
to the secure analytical environment at ICES to create a
combined two-province study data set. The linked data
sets from the two provinces will then be pooled within
the secure analytical environment at ICES to create an
Integrated Pediatric Health Data Repository (see online
supplemental file 1). While we anticipate a high success
rate of linking the bronchiolitis clinical data sets to HAD,
it is possible that some children may not be matched due
to unavailability of health card number. If we identify a
significant number of patients with an unavailable health
card number, we will use a probabilistic approach for
these patients to link their bronchiolitis clinical trial data
to HAD.
3
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METHODS
Study design
We will conduct a longitudinal cohort study by linking
clinical data from two emergency department (ED)-based
bronchiolitis studies (CanBEST and BSC) with routinely
collected HAD.
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Approaches and analysis
Objective 1: quantify the risk of developing asthma by age 5
and 10 years in children treated with high-dose corticosteroid and epinephrine for bronchiolitis during infancy.
1. Risk estimation: risk of asthma by age 5 and 10 years
will be assessed by comparing children diagnosed with
bronchiolitis who received high-
dose corticosteroid
and epinephrine (exposed group, N=180) to those
who did not receive high-dose corticosteroid and epinephrine for treatment of bronchiolitis (nonexposed
group, N=1050). The nonexposed group will comprise:
(1) children in CanBEST who received only epinephrine or only placebo as treatment and (2) children in
the BSC study (none of whom received high-dose corticosteroid treatment). To determine incident asthma

by age 5 and 10 years (the primary outcome) of these
children, their health service utilisation record will be
followed through the HADs. Asthma incidence will be
ascertained when the child is of 2 years of age.
2. Statistical analysis: the unadjusted effects of high-dose
corticosteroid and epinephrine on later asthma development will be assessed using Cox proportional hazards regression analysis. Because treatment assignment
will be nonrandom, we will compare outcomes after
controlling for clinical and health service utilisation-
related factors using multivariable adjustment analysis.
For our risk-adjusted comparison, multivariable Cox
proportional hazards regression modeling will be performed to determine the effect of high-dose corticosteroid and epinephrine after simultaneously adjusting
for prespecified risk factors. Adjusted HR with 95% CI
will be generated to estimate the effect of high-dose
corticosteroid and epinephrine. Since asthma incidence has been shown to decrease with age, we plan to
perform separate analyses for diagnosis of asthma by
age 5 and 10 years.1
Objective 2: identify risk factors associated with development of asthma by age 5 and 10 years in children diagnosed
with bronchiolitis during infancy.
1. Probable risk factors include clinical factors: age at
diagnosis of bronchiolitis, sex, RDAI score on ED
presentation with bronchiolitis, receipt of RSV immunoglobulin, presence of comorbidities, specific viral
pathogen, disease severity (based on hospital admission
or ICU admission); early childhood factors (breastfeeding and daycare); environmental factors (tobacco
smoke at home); sociodemographic factors and health
service utilisation-
related factors: respiratory-
related
health service use (number of hospitalisations, ED or
physician office visits) in the 2-year period following
bronchiolitis for acute LRTI, total days of hospital admission for acute LRTI and receipt of primary immunisations by age 2 years.
2. Statistical analysis: multivariable Cox proportional hazards regression analysis will be performed to identify
significant covariates. Risk estimate of covariates will
be presented as adjusted HR with 95% CI.
Objective 3: develop asthma prediction models for children diagnosed with bronchiolitis during infancy.
1. Prediction modelling: models predicting asthma at age
5 and 10 will be generated using multivariable logistic
regression analysis. A forward stepwise method (with
entrance tolerances of 0.05) will be used to determine
significant predictors for inclusion in the regression
models. Collinearity and correlation will be analysed
before model fitting. We will internally validate our
models and assess their predictive accuracy by discrimination (area under the curve) and calibration (by
plotting observed vs predicted number of outcomes).
Internal validation will be performed using bootstrapping method.53 Potential clinical predictors: age<6
months at diagnosis of bronchiolitis, sex, high RDAI
score on ED presentation with bronchiolitis, receipt
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Outcome measures and predictors
Outcome measure
Our primary outcome is the cumulative incidence of asthma
by age 5 and 10 years. We will define asthma using a validated health administrative case definition, which has been
shown to have 89% sensitivity and 72% specificity to identify
asthma in children aged 0–17 years.48 49 Previous studies have
used this case definition to identify asthma in the paediatric
population,18 50 and it has also been used by the Canadian
Chronic Disease Surveillance System to identify asthma cases
from provincial HAD that includes Ontario and Alberta.51
Covariates
Important covariates (all measured in CanBEST and BSCS)
will include clinical risk factors: gestational age at birth, birth
weight, age at bronchiolitis diagnosis, infant sex, personal
history of atopy, maternal and family history of asthma,
smoking exposure (maternal and environmental), breastfeeding, daycare attendance, respiratory distress assessment
index (RDAI), receipt of RSV immunoglobulin, presence
of comorbidities, type of viral pathogen, disease severity
(based on hospital admission or ICU admission) and type
and dosage of medications. Socioeconomic status will be
measured using the Canadian/Ontario marginalisation
index.52 We will use HAD to measure: respiratory-related
health service use (number of hospitalisations, ED or physician office visits) for acute lower respiratory tract infections
(LRTI), total days of hospital admission for acute LRTI and
receipt of primary immunisations. Counts for respiratory-
related health service use will be accrued from the time the
child is diagnosed with bronchiolitis until reaching 2 years
of age.
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Data storage and analysis
Once the data have been transferred and linked, it will
be retained in the secure environment of ICES. ICES will
assign an ICES key number (IKN) for each subject in the
linked database. Only the IKN will be provided in the
data set containing the various variables for analysis, the
Ontario health card number will not be provided. Data
analysis will be performed through ICES Data & Analytic
Services.

Open access

Study power
Objective 1: risk of developing asthma by age 5 and 10
years in children treated with high-dose corticosteroid and
epinephrine for bronchiolitis during infancy. Evidence
has shown in children diagnosed with bronchiolitis during
infancy, the proportion of children with asthma between
the ages of 5 and 10 years to range from 20% to 54%.4–12
With 180 subjects in the exposed group (total number of
children who received combined therapy of high-dose corticosteroid and epinephrine in CanBEST) and a minimum
of 180 subjects in the nonexposed group and assuming an
asthma proportion of 35% in the nonexposed group, we will
have >80% power to detect an absolute difference in proportion of at least 14% between the exposed and nonexposed
group. A sensitivity analysis showing the power for varying
proportions of children with asthma in the exposed group is
included in online supplemental file 2.
Objective 3: develop asthma prediction models for children diagnosed with bronchiolitis during infancy. We will use
data from CanBEST and BSCS studies (N=1440). A well-used
‘rule of thumb’ for multivariable prediction model sample
size is to ensure at least 10 outcome events per predictor
before selection of the model. We will follow criteria set by
Riley et al to account for minimum overfitting of data.55 56

PATIENT AND PUBLIC INVOLVEMENT
Patients were not involved in the development of the study
research question, outcome methods or design of the study
and will not be involved in the conduct of the study.

ETHICS AND DISSEMINATION
We have received ethics approval of our study from all four
sites of the study. ICES is an independent, nonprofit research
Abdullah K, et al. BMJ Open 2021;11:e048823. doi:10.1136/bmjopen-2021-048823

institute whose legal status under Ontario’s health information privacy law allows it to collect and analyse healthcare
and demographic data, without consent, for health system
evaluation and improvement. As part of our integrative
knowledge translation plan, we have consulted clinicians
across the spectrum of paediatric care in the development
of the study and will continue this consultation at key stages
of the study (eg, evaluating results). Our end-of-grant knowledge translation plan includes dissemination of study findings to the academic community, relevant stakeholders and
to the public through presentations at international paediatric, emergency medicine and respirology meetings and
publication in peer-reviewed journals.
DATA DISPOSITION
The data set from this study will be held securely in coded
form at ICES. While data sharing agreements prohibit ICES
from making the data set publicly available, access may be
granted to those who meet prespecified criteria for confidential access, available at www.ices.on.ca/DAS. The full data
set creation plan and underlying analytic code will be available from the authors on request, understanding that the
computer programs may rely on coding templates or macros
that are unique to ICES and, therefore, either inaccessible or
may require modification.
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of RSV immunoglobulin, presence of comorbidities
such as congenital heart disease, presence of RSV viral pathogen, severe disease (based on hospital admission or ICU admission), breastfeeding <3 months,
no daycare attendance, tobacco smoke at home and
low socioeconomic status. Potential health service
utilisation-
related predictors: volume of respiratory-
related health service use (number of hospitalisations,
ED or physician office visits) for acute LRTI>7 days of
hospital admission for acute LRTI and complete receipt of primary immunisations by age 2 years.
2. Comparison between models developed using only
clinical predictors to those developed using both
clinical and health service utilisation-related predictors: we will compare the incremental performance
of models developed using only clinical variables to
those developed using both clinical and health service
utilisation-related variables. Incremental improvement
in outcome prediction will be determined by examining the change in the area under the receiver–operating characteristic curve, net reclassification index and
integrated discrimination improvement.54
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